Quoin CFO granted option on 85,250 ADS

Quoin Pharmaceuticals (QNRX) reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor.

Rhea-AI Filing Summary

Quoin Pharmaceuticals (QNRX) reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor. On February 4, 2026, she received an option to purchase 85,250 American Depositary Shares (ADS) at an exercise price of $7.37 per ADS.

The option covers ADSs, each representing thirty-five ordinary shares of Quoin Pharmaceuticals. The award vests over four years, with 20% vesting on each of February 4, 2027, 2028 and 2029, and the remaining 40% vesting on February 4, 2030. The option expires on February 4, 2036 and is held directly by the CFO.

Insider Trade Summary

Grant/Award: 85,250 shares

Grant/Award 1 txn

Insider Lawlor Sally Bridget

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	85,250	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 85,250 contracts (Direct)

Footnotes (2)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quoin Pharmaceuticals (QNRX) disclose for its CFO?

Quoin Pharmaceuticals disclosed that CFO Sally Bridget Lawlor received a stock option on February 4, 2026 to buy 85,250 ADS. This derivative award is a compensation grant, not an open‑market purchase, and gives her the right to acquire ADS at a fixed exercise price.

What is the exercise price and structure of the QNRX CFO stock option grant?

The CFO’s option has an exercise price of $7.37 per American Depositary Share (ADS). Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals, so the grant is structured in ADS units, aligning compensation with the company’s ADS trading instrument.

How does the Quoin Pharmaceuticals (QNRX) CFO option vest over time?

The option vests in four annual installments: 20% on each of February 4, 2027, 2028 and 2029, and 40% on February 4, 2030. This multi-year schedule is designed to align the CFO’s potential equity gains with longer-term company performance.

When does the Quoin Pharmaceuticals (QNRX) CFO stock option expire?

The stock option granted to Quoin’s CFO expires on February 4, 2036. After that date, any unexercised portion of the 85,250 ADS option will lapse, meaning it can no longer be used to purchase ADS at the fixed exercise price.

Is the QNRX CFO’s option grant a direct or indirect holding?

The filing shows the 85,250 ADS stock option as a direct holding of CFO Sally Bridget Lawlor. There is no indication of indirect ownership through entities or trusts, and no footnote disclaiming beneficial ownership rights over the granted derivative security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawlor Sally Bridget

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		85,250(1)		(2)	02/04/2036	ADS	85,250(1)	$0	85,250(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Sally Bridget Lawlor	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.